Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Atomo Diagnostics Ltd. ( (AU:AT1) ) has shared an announcement.
Atomo Diagnostics Limited reported a 7% increase in revenues to AUD 2,052,476 for the half-year ended December 31, 2024, while also reducing its loss from ordinary activities after tax by 12% to AUD 2,758,734. Despite the improvements in revenue and reduced losses, the company did not declare any dividends, and its net tangible assets per ordinary security decreased from 1.25 AUD cents to 0.87 AUD cents, indicating a potential area of concern for stakeholders.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Limited operates in the medical diagnostics industry, focusing on the development and commercialization of rapid diagnostic test devices. The company is known for its innovative products that aim to improve healthcare accessibility and efficiency.
Average Trading Volume: 204,105
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$12.78M
For a thorough assessment of AT1 stock, go to TipRanks’ Stock Analysis page.